| Identification | Back Directory | [Name]
doxorubicin(6-maleimidocaproyl)hydrazone | [CAS]
151038-96-9 | [Synonyms]
INNO-206
DOXO-EMCH
MC-DOXHZN
Doxorubicin-EMCH
INNO-206 (Aldoxorubicin)
Doxorubicin-hydrazone-caproyl-maleimide
doxorubicin(6-maleimidocaproyl)hydrazone
DOXO-EMCH; DOXORUBICIN-EMCH; INNO206;INNO 206;ALDOXORUBICIN
N'-[(1E)-1-{4-[(3-Amino-2,3,6-trideoxyhexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexane hydrazide
1H-Pyrrole-1-hexanoicacid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
(E)-N'-(1-((2R,4R)-4-((2S,4R,5R,6R)-4-aMino-5-hydroxy-6-Methyltetrahydro-2H-pyran-2-yloxy)-2,5,12-trihydroxy-7-Methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide | [EINECS(EC#)]
200-258-5 | [Molecular Formula]
C37H42N4O13 | [MDL Number]
MFCD15146982 | [MOL File]
151038-96-9.mol | [Molecular Weight]
750.75 |
| Hazard Information | Back Directory | [Uses]
Doxorubicin-hydrazone-caproyl-maleimide is an albumin-binding prodrug of doxorubicin and a promising clinical candidate for the treatment of a broad range of solid tumors | [Biological Activity]
the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (inno-206), formerly known as doxo-emch, is a prodrug of the anticancer agent doxorubicin which selectively binds to the cys34 of circulating albumin and accumulates in solid tumors due to passive targeting[1]. inno-206 shows significantly superior antitumor efficacy over free doxorubicin in a spectrum of preclinical tumor models [2]. | [in vivo]
in a murine renal cell carcinoma model and in breast carcinoma xenograft models, inno-206 has shown superior activity over doxorubicin. inno-206 has shown more potent antitumor efficacy than free doxorubicin in the tumor models and is thus a promising clinical candidate for treating a broad range of solid tumors [2]. | [References]
[1]. kratz f. doxo-emch (inno-206): the first albumin-binding prodrug of doxorubicin to enter |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.is0513.com/ShowSupplierProductsList15748/0.htm |
| Company Name: |
Lynnchem
|
| Tel: |
86-(0)29-85992781 17792393971 |
| Website: |
http://www.lynnchem.com/ |
|